2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $6.2B | $7.9B | $9B | $9.8B | $12B |
Cost of Revenue | $5.5B | $7B | $7.8B | $8.4B | $9.9B |
Gross Profit | $703M | $968M | $1.2B | $1.4B | $1.9B |
Gross Profit % | 11% | 12% | 14% | 14% | 16% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | -$22M | $161M | $200M | $229M | $134M |
Dep. & Amort. | $323M | $335M | $329M | $361M | $415M |
Def. Tax | -$27M | -$62M | -$10M | -$41M | $0 |
Stock Comp. | $25M | $28M | $33M | $35M | $39M |
Chg. in WC | $34M | $3M | $4M | -$53M | -$29M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $328M | $333M | $495M | $468M | $413M |
ST Investments | $0 | $0 | $0 | $0 | $0 |
Cash & ST Inv. | $328M | $333M | $495M | $468M | $413M |
Receivables | $1.2B | $1.5B | $1.6B | $1.8B | $1.8B |
Inventory | $0 | $0 | $0 | $0 | $0 |
GXO reported record revenue of $11.7 billion for 2024, a 20% increase year-over-year, with 3% organic growth. Adjusted EBITDA for the year was $815 million, exceeding updated guidance.
The company achieved over $1 billion in new business wins for the second consecutive year, including a landmark $2.5 billion healthcare contract and significant growth in Germany, its fastest-growing market.
For 2025, GXO expects 3%-6% organic revenue growth and adjusted EBITDA between $840 million and $860 million, with sequential improvement throughout the year despite Q1 impacts from customer capacity realignments and new site ramp-ups.
GXO continues to invest in AI-enabled warehouse technology, reporting significant productivity improvements and planning to scale these tools across its operations in 2025 to enhance differentiation and efficiency.
The company is focused on deleveraging and integration following the Wincanton acquisition, with M&A off the short-term agenda. Free cash flow conversion is expected to remain at 25%-35% for 2025.